Healthcare
RVL Pharmaceuticals plc(RVLPQ)
Live Price
Offline$0.00001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 โ Jun 16, 2026
- Market Cap
- โ
- Revenue Growth
- +184.1%
- EPS Growth
- +39.6%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 23, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
RVL Pharmaceuticals plc (RVLPQ) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of +184.1%, EPS growth of +39.6%, a dividend yield of 0.0%. What stands out right now is revenue +184.1%, EPS +39.6%, free cash flow +31.8% with operating margin -91.9% and ROIC -41.3%. Valuation is more restrained than many high-expectation growth names at price/sales 0.1. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines RVLPQ price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+184.1% vs +7.6% peer median
Operating Margin
Below sector median
-91.9% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +184.1% and EPS at +39.6%, with operating margin around -91.9%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | +0.0% | +0.0% | +0.0% |
2026 Mar 16, 2026 | โ | +0.0% | +0.0% | +0.0% |
2025 Apr 1, 2025 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RVLPQ
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
RVLPQ Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RVLPQ and SPY.
Company Overview
RVL Pharmaceuticals plc
Other OTC
RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
- Leadership
- Brian A. Markison
- IPO Date
- Oct 18, 2018
- Employees
- 125
- Street Address
- 400 Crossing Boulevard
- Mailing
- Bridgewater, NJ, 08807
- Region
- Bridgewater, NJ, US
- Reporting Currency
- USD
- Investor Line
- 908 809 1300
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 0.1
- Price/Book
- 0.0
Growth
- Revenue
- +184.1%
- EPS
- +39.6%
- Free Cash Flow
- +31.8%
Profitability
- Gross Margin
- 81.0%
- Operating Margin
- -91.9%
- Net Margin
- -104.0%
- ROE
- -80.9%
- ROIC
- -41.3%
Balance Sheet
- Debt/Equity
- 1.13
- Current Ratio
- 2.89
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.